Merck, an American multinational pharmaceutical company headquartered in Rahway, New Jersey, led a $221m Series B round in Orna Therapeutics, a biotechnology company pioneering a new class of fully engineered circular RNA therapies, with participation from MPM Capital and BioImpact Capital. "In under three years, Orna has taken proprietary circular RNA from academic literature to the first proof of concept data in preclinical models. Investors continue to recognize our premier technology and the hard work of our team, and we are pleased to see such unwavering belief in the potential of circular RNA to revolutionize how we treat disease," Tom Barnes, Orna CEO.